US Stock MarketDetailed Quotes
IPA ImmunoPrecise Antibodies
- 0.820
- +0.008+0.96%
Close Aug 6 16:00 ET
- 0.812
- -0.008-0.94%
Post 20:01 ET
22.39MMarket Cap-1066P/E (TTM)
0.830High0.750Low29.00KVolume0.800Open0.812Pre Close23.44KTurnover0.12%Turnover RatioLossP/E (Static)27.30MShares2.60052wk High0.91P/B19.47MFloat Cap0.75052wk Low--Dividend TTM23.74MShs Float33.340Historical High--Div YieldTTM9.85%Amplitude0.750Historical Low0.808Avg Price1Lot Size
ImmunoPrecise Antibodies Key Stats
Quarterly+Annual
YOY
| (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | (Q1)Jul 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 18.65%24.52M | 14.91%6.46M | 20.31%6.22M | 18.63%6.15M | 21.31%5.69M | 6.72%20.67M | 7.29%5.62M | 7.39%5.17M | 9.78%5.18M | 2.20%4.69M |
| Operating revenue | 18.65%24.52M | 14.91%6.46M | 20.31%6.22M | 18.63%6.15M | 21.31%5.69M | 6.72%20.67M | 7.29%5.62M | 7.39%5.17M | 9.78%5.18M | 2.20%4.69M |
| Cost of revenue | 36.95%12.47M | 46.97%3.35M | 37.02%3.02M | 32.89%3.2M | 30.90%2.89M | 8.60%9.1M | 18.56%2.28M | -0.99%2.21M | 12.02%2.41M | 6.15%2.21M |
| Gross profit | 4.24%12.05M | -6.97%3.11M | 7.86%3.2M | 6.30%2.95M | 12.75%2.8M | 5.28%11.56M | 0.75%3.34M | 14.62%2.96M | 7.92%2.78M | -1.08%2.48M |
| Operating expense | -30.56%25.82M | -2.33%6.62M | -13.09%6.54M | -43.71%5.96M | -45.53%6.69M | 34.42%37.17M | -10.57%6.78M | 9.70%7.52M | 46.18%10.59M | 108.83%12.28M |
| Selling and administrative expenses | 0.76%19.14M | 9.81%5.03M | -2.45%4.83M | -9.01%4.23M | 8.03%5.68M | 5.18%18.99M | -20.74%4.58M | 14.19%4.95M | 25.11%4.65M | 30.63%5.25M |
| -Selling and marketing expense | -1.80%3.54M | -2.68%909K | -22.37%649K | 12.73%921K | 4.01%1.06M | 34.73%3.61M | 8.10%934K | 2.96%836K | 41.84%817K | 526.99%1.02M |
| -General and administrative expense | 1.36%15.59M | 13.00%4.12M | 1.61%4.18M | -13.65%3.31M | 9.00%4.61M | 0.04%15.38M | -25.81%3.65M | 16.79%4.11M | 22.05%3.83M | 9.67%4.23M |
| Research and development costs | -71.33%4.04M | 1.64%927K | -35.96%1M | -79.27%1.04M | -92.74%449K | 84.01%14.1M | -31.12%912K | -24.05%1.56M | 64.32%5M | 452.73%6.19M |
| Depreciation amortization depletion | -32.76%2.97M | -46.77%701K | -31.36%709K | -25.39%711K | -23.83%847K | 119.27%4.41M | 162.35%1.32M | 105.78%1.03M | 89.09%953K | 65.97%1.11M |
| -Depreciation and amortization | -32.76%2.97M | -46.77%701K | -31.36%709K | -25.39%711K | -23.83%847K | 119.27%4.41M | 162.35%1.32M | 105.78%1.03M | 89.09%953K | 65.97%1.11M |
| Other operating expenses | 0.30%-331K | -23.08%-32K | ---- | -14.29%-16K | -4.81%-283K | -342.67%-332K | -36.84%-26K | 38.89%-22K | 26.32%-14K | -485.71%-270K |
| Operating profit | 46.27%-13.76M | -2.18%-3.52M | 26.72%-3.34M | 61.50%-3.01M | 60.27%-3.89M | -53.61%-25.61M | 19.38%-3.44M | -6.72%-4.56M | -67.27%-7.81M | -190.43%-9.8M |
| Net non-operating interest income expense | -95.65%4K | -1,645.45%-340K | -105.13%-2K | 477.78%208K | 2,860.00%138K | -52.58%92K | -75.28%22K | -71.94%39K | 357.14%36K | 94.95%-5K |
| Non-operating interest income | -81.15%23K | -785.71%-336K | -92.31%3K | 491.67%213K | --143K | -56.27%122K | -55.05%49K | -75.63%39K | 500.00%36K | ---- |
| Non-operating interest expense | -36.67%19K | -85.19%4K | --5K | --5K | 0.00%5K | -64.71%30K | 35.00%27K | --0 | --0 | -95.15%5K |
| Other net income (expense) | -569.28%-14.95M | -504.20%-14.97M | -51.32%-115K | -29.63%209K | -408.70%-71K | -453.88%-2.23M | -1,203.68%-2.48M | -114.79%-76K | 318.38%297K | -94.68%23K |
| Gain on sale of security | -62.11%86K | 482.35%65K | -51.32%-115K | -29.63%209K | -408.70%-71K | -64.03%227K | 91.05%-17K | -114.79%-76K | 318.38%297K | -94.64%23K |
| Special income (charges) | -511.02%-15.03M | ---- | ---- | ---- | ---- | ---2.46M | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | 511.02%15.03M | ---- | ---- | ---- | ---- | --2.46M | ---- | ---- | ---- | ---- |
| Income before tax | -3.43%-28.7M | -219.23%-18.82M | 24.77%-3.46M | 65.36%-2.59M | 60.89%-3.83M | -75.11%-27.75M | -34.95%-5.9M | -27.00%-4.6M | -55.16%-7.48M | -221.63%-9.78M |
| Income tax | -28.02%-1.53M | -1.30%-777K | -597.12%-517K | 125.40%32K | 34.99%-262K | -238.44%-1.19M | -378.91%-767K | -50.00%104K | -166.32%-126K | -314.36%-403K |
| Net income | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 64.33%-2.62M | 62.00%-3.57M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M | -46.76%-7.35M | -190.43%-9.38M |
| Net income continuous Operations | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 64.33%-2.62M | 62.00%-3.57M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M | -46.76%-7.35M | -190.43%-9.38M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 64.33%-2.62M | 62.00%-3.57M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M | -46.76%-7.35M | -190.43%-9.38M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 64.33%-2.62M | 62.00%-3.57M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M | -46.76%-7.35M | -190.43%-9.38M |
| Basic earnings per share | 0.93%-1.06 | -233.33%-0.7 | 42.11%-0.11 | 66.67%-0.1 | 63.16%-0.14 | -25.88%-1.07 | 8.70%-0.21 | 5.00%-0.19 | -15.38%-0.3 | -123.53%-0.38 |
| Diluted earnings per share | 0.93%-1.06 | -233.33%-0.7 | 42.11%-0.11 | 66.67%-0.1 | 63.16%-0.14 | -25.88%-1.07 | 8.70%-0.21 | 5.00%-0.19 | -15.38%-0.3 | -123.53%-0.38 |
| Dividend per share | ||||||||||
| Currency Unit | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg